Examination of effectiveness of combination therapy of periodontal tissue regeneration drug, Regroth, and carbonate apatite, Cytrans Granules, for periodontal tissue regenaration - Study on combination therapy of Regroth and Cytrans Granules for periodontal tissue regeneration

开始日期2019-11-01

申办/合作机构

The University of Tokushima

JPRN-jRCTs051190045

/ CompletedN/AIIT

The clinical study to evaluate the safety and efficacy of combination therapy of REGROTH and Cytrans Granules for periodontitis patients.

开始日期2019-08-27

申办/合作机构-

100 项与曲弗明相关的临床结果

登录后查看更多信息

100 项与曲弗明相关的转化医学

登录后查看更多信息

100 项与曲弗明相关的专利（医药）

登录后查看更多信息

105

项与曲弗明相关的文献（医药）

2025-05-01·Journal of Biomaterials Applications

Injectable ADM temperature-sensitive hydrogel loaded with bFGF in diabetic rat wound healing study

Article

作者: Liu, Wenyang ; Sun, Jianping ; Chen, Haojiao

Background: Diabetic wound is one of the most common diabetic chronic complications. Effective treatments of diabetic wound remain limited. Here, we explored the effects of basic fibroblast growth factor (bFGF)-acellular dermal matrix (ADM) hydrogel on the diabetic wound. Methods: The bFGF-ADM hydrogel was manufactured by mixing 180 µL ADM hydrogel and 20 µL bFGF aqueous solution (10 mg/mL). The morphology of ADM hydrogel and bFGF-ADM hydrogel was observed under scanning electron microscope. The release property of bFGF-ADM hydrogel was determined by ELISA. CCK-8 assay was utilized to estimate the cell viability of mouse skin fibroblasts. The diabetes mellitus (DM) model was established in rats. The four wounds on the back of each DM rat were treated with the ADM hydrogel, bFGF-ADM hydrogel, bFGF aqueous solution and no solution (control), respectively. The wound healing rate of each rat was estimated. The traumatized skin tissue of each rat was observed by H&E staining and Sirius red staining. Results: The bFGF-ADM hydrogel displayed an interconnected pore structure and bFGF was gradually released from the bFGF-ADM hydrogel over time. The bFGF-ADM hydrogel could enhance the cell viability of skin fibroblasts and promote the wound healing rate, the re-epithelialization of wound and increase the collagen fiber content of dermis. And the bFGF-ADM hydrogel exhibited better therapeutic effects of diabetic wound than either bFGF or ADM alone. Conclusions: Our study revealed that the bFGF-ADM hydrogel could promote diabetic wound healing.

2025-03-01·Injury

A nurse-led approach to enhancing foot and ankle tissue repair: A study using fibroblast growth factor and skin flap technique

Article

作者: Yang, Fan ; Dong, Jing ; Hu, Jing ; Mendame Ehya, Regis Ernest ; Jiang, Zhezhen

INTRODUCTIONFoot and ankle soft tissue defects with exposed bone pose significant challenges in wound healing and patient satisfaction OBJECTIVE: The study aims to assess the impact of nursing care quality and patient satisfaction on optimizing outcomes for complex foot and ankles injuries, focusing on the timing of rh-FGF administration after reconstructive surgery METHODS: This study included eighteen patients (15 males and 3 females) with traumatic foot and ankle soft tissue defects and exposed bone wounds, treated between January 2021 and December 2022. Patients were randomly assigned to three groups, underwent reconstructive surgery, and received rh-bFGF at varying times postoperatively. Key outcomes included wound healing time, hospital stay duration, satisfaction with nursing care scale, American Orthopedic Foot and Ankle Society (AOFAS) score, and Visual Analogue Scale for pain. All patients were followed for at least three months RESULTS: The study population had an average age of 41.1 years, with a range from 16 to 74 years. Findings indicated an average hospital stay of 17 days and a corresponding wound healing time of 17 days. At three months post-operation, the average American Orthopedic Foot and Ankle Society (AOFAS) score was 88. A notable 88.9 % of patients expressed satisfaction with the attentiveness of nursing staff and the privacy afforded to them. Furthermore, 84.3 % rated the nurses' competence positively, and 83.3 % appreciated the support provided to family and friends, along with personalized care and nurses' expertise in patient management. The results demonstrated a consistent trend of improvement in all assessed outcomes across the three treatment groups. Patients in Group 1, who received rh-bFGF one day after surgery, demonstrated the most favorable outcomes. This was followed by Group 3, which received rh-bFGF until ischemic changes were noted. In contrast, Group 2, which received rh-bFGF once inflammatory granulation had subsided, exhibited the least improvement CONCLUSION: The results of this study highlight the crucial role of timing in the administration of rh-bFGF for optimizing soft tissue repair in patients with foot and ankle defects. Timely application of rh-bFGF post-surgery is essential for achieving favorable patient outcomes, improving patient satisfaction with nursing care, and facilitating faster recovery.

2025-01-01·[Rinsho ketsueki] The Japanese journal of clinical hematology

[Improvement of extensive epidermolysis due to severe acute graft-versus-host disease through long-term multidisciplinary skin care].

Article

作者: Uemura, Noriko ; Momose, Yuko ; Yoshifuji, Kota ; Uchiyama, Akiko ; Chubachi, Nagisa ; Kashiwagi, Kumi ; Motomura, Yotaro ; Ouchi, Fumihiko ; Nagao, Toshikage ; Mori, Takehiko ; Takimoto, Yuri ; Nakata, Yasumasa

A 41-year-old woman with myelodysplastic syndrome underwent unrelated bone marrow transplantation following conditioning with fludarabine, busulfan, total body irradiation, and anti-thymocyte globulin. She received tacrolimus and short-term methotrexate for graft-versus-host disease (GVHD) prophylaxis. After engraftment, she developed acute GVHD involving the skin, gut, and liver. Even after treatment with glucocorticoids, human mesenchymal stem cells, and ruxolitinib, skin GVHD progressed and caused extensive epidermolysis and erosions with persistent bleeding. The patient was started on a daily skin care regimen, which included washing, application of dimethyl isopropylazulene and betamethasone ointment, and topical trafermin and hydrogel wound dressing for bleeding sites. A multi-disciplinary team consisting of hematologists, plastic surgeons, and nurses, and physical therapists, psychiatrists/clinical psychologists, and palliative care providers for physical, mental, and pain supportive care managed the patient's care. After 4 months of treatment under this team, complete epithelial regeneration was achieved. This case demonstrates the efficacy of local skin care and multi-disciplinary collaboration in acute GHVD causing extensive skin damage.

项与曲弗明相关的新闻（医药）

2025-04-08

·FierceBiotech

KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal

If approved, sebetralstat would be the first oral on-demand treatment for hereditary angioedema available in Japan.\n As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has sold the Japanese rights to the drug to Kaken Pharmaceutical for $11 million upfront.Alongside the upfront fee, Tokyo-based Kaken has also agreed a further $11 million payment if a regulatory milestone is hit next year. There are additional commercial milestone payments tied to the deal should sebetralstat get approved in Japan, but KalVista didn’t go into details in its April 8 release.Royalties tied to the deal would be based on the drug’s price in Japan, with a royalty rate “as a percentage of sales approximately in the mid-twenties,” KalVista explained.HAE is a genetic disease marked by low levels or dysfunction of the C1 inhibitor. Patients can be struck with bouts of severe swelling across the body, and attacks can be fatal if they impact the lungs.The FDA is expected to make a call on whether to approve sebetralstat, an oral plasma kallikrein inhibitor, in the U.S. in June as an on-demand treatment for HAE attacks in adult and pediatric patients aged 12 years and older. The application was based on a phase 3 study last year that showed patients who received either a 300-mg or 600-mg dose of sebeltralstat experienced quicker symptom relief by roughly four hours each compared to placebo.KalVista has also submitted sebetralstat to regulators in Japan. If approved, it would be the first oral on-demand treatment for HAE available in the country, the biotech noted. Kaken already markets an array of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics, tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia and—most recently—Alumis’ late-stage TYK2 inhibitor as a dermatology treatment“We are pleased to partner with Kaken, whose expertise and demonstrated success in the region make them well-suited to work alongside our exceptional team to bring sebetralstat to the HAE community in Japan,” KalVista CEO Ben Palleiko said in the release.“This collaboration is an important part of our strategy to expand the global reach of sebetralstat as we prepare for several commercial launches starting this year,” Palleiko added.Even if sebetralstat gets the nod from the FDA in the June, it may only have a few weeks’ headstart on donidalorsen, Ionis Pharmaceuticals’ RNA-targeted medicine for preventing HAE attacks, which is expecting a decision in August. Meanwhile, CSL secured EU approval for its prophylactic HAE drug garadacimab in February, while Intellia has a CRISPR-based gene editing candidate in development.

临床3期临床结果上市批准引进/卖出基因疗法

2025-03-25

·FierceBiotech

Kaken agrees to $180M deal to develop Alumis\' lead TYK2 inhibitor in Japan

Tokyo-based Kaken Pharmaceutical has committed $40 million in upfront and near-term co-development payments over this year and 2026.\n Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan.The drug in question, dubbed ESK-001, is Alumis’ lead candidate and is designed to correct immune dysregulation in diseases driven by proinflammatory mediators, including well-known targets like IL-23, IL-17, and type 1 interferon. Alumis has already been evaluating the twice-daily modified-release oral formulation in a pair of phase 3 trials in adults with moderate to severe plaque psoriasis.Alongside that late-stage program, Alumis is also running a phase 2b trial of ESK-001 in patients with systemic lupus erythematosus, which is expected to read out next year. The biotech said it “continues to leverage its precision data analytics platform to explore ESK-001’s potential application in other immune-mediated conditions” and is also working on a once-daily formulation.Tuesday morning\'s deal sees Tokyo-based Kaken commit $40 million in upfront and near-term codevelopment payments over this year and next, with the potential to pay up to $140 million in further milestone payments and field option payments as well as tiered royalties.In return, Kaken has the rights to ESK-001 as a dermatology drug in Japan and will be responsible for clinical and regulatory development along with commercialization in the country. There is also the option for Kaken to expand the licensing deal to cover rheumatological and gastrointestinal diseases. “We strongly believe in the potential of ESK-001 to address a range of medical needs in the dermatology space and potentially rheumatological and gastrointestinal diseases in the future,” Hiroyuki Horiuchi, president and representative director of Kaken, said in the March 25 release.Kaken markets a number of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics and tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia.“ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions,” Horiuchi added in the release.Immune-mediated disease specialist Alumis is currently in the process of buying Acelyrin. Alumis’ pipeline is headed up by ESK-001, with the company sharing phase 2 data a year ago that showed the drug met its primary endpoint of the proportion of patients achieving a 75% improvement in the psoriasis area and severity score at Week 12 compared to placebo.“This partnership builds on the positive phase 2 clinical data of ESK-001, our next-generation oral TYK2 inhibitor, supporting our objectives to unlock its full therapeutic potential and ensure ESK-001 is widely accessible to people with immune-mediated disorders around the world,” Alumis CEO Martin Babler said in this morning’s release.

$Kaken agrees to $180M deal to develop Alumis\' lead TYK2 inhibitor in Japan$

临床2期引进/卖出临床3期临床结果免疫疗法

2024-11-07

·药事纵横

诱导多能干细胞衍生间充质干细胞疗法的研究进展及创新策略（一）

前言：间充质干细胞治疗的有效性与安全性已在多种疾病中得到证实。然而成体来源的间充质干细胞其体外扩增能力有限性、分离细胞的高异质性导致的临床结果的不稳定性等问题亟待解决。将iPSC通过特定实验路线诱导分化为iPSC衍生的间充质样MSC（iPSC-MSC），是最有潜力替代成体MSC的产品。许多研究证明iPSC可以通过多种分化策略获得iPSC-MSC，且经研究表明iPSC-MSC与成体MSC相比，其增殖能力、免疫调节能力、生物学效能等特点均优于成体MSC或与之相当。笔者试图通过检索相关文献资料，从iPSC-MSC制备的方法学研究、iMSC产品在不同疾病模型中的应用、临床级iPSC衍生细胞制品的最新研究进展以及新一代的iPSC衍生产品的开发策略等四个方面，与广大读者探讨此类细胞治疗产品的开发前景，抛砖引玉，以期展开对类似管线的开发前景的讨论，从而丰富产品开发思路。再生医学和细胞治疗已成为当今世界各国先进生物医疗技术关注的焦点，其中间充质干细胞（Mesenchymal stem cell, MSC）疗法潜力无限，已被证明在多种疾病的临床试验研究中具备安全性和有效性，广受关注。MSC属于成体多能干细胞，因其多向分化潜能高、免疫原性低及伦理问题少和来源广泛等特点，一直作为干细胞研究的重要方向[1]。MSC具有免疫调节、抗炎、支持造血功能、组织修复等功能特性[2]，可应用于自身免疫性疾病如红斑狼疮、炎性疾病如骨关节炎、衰老相关疾病、感染性疾病的治疗[3]。然而由于不同的MSC细胞来源、供体情况不同、培养体系差异等造成的细胞异质性、体外扩增能力的有限性、分离提取的难度与局限性等[4]，使得MSC细胞疗法在临床应用方面存在一些限制和效果的不稳定[5]。由iPSC获得iPSC-MSC的方法学研究进展笔者汇总了目前市面上的主流iPSC衍生MSC（iMSC）的制备方法[6]。分化方向大致可归类为三个方面，主流分化策略包括：MSC培养基替换诱导法、信号通路调节诱导法及拟胚体法等[7]。在下文中，对每种报道的研究方案使用的关键物料与方法细节进行了详细描述，各项研究也对衍生的iMSC进行了细胞表面标志物与多向分化潜能的评估，同时也针对每种方案的整体分化时间做了统计，以期找到一种高效且安全的可用于工业化生产的分化方案。（1）MSC培养基替换诱导法通过将iPSC培养基更换为MSC培养体系，能够诱导iPSC的自发分化，起到对细胞的诱导和筛选作用。MSC基础培养基成分包括高/低糖DMEM、KO-DMEM（特定成分敲除的DMEM）、DMEM-F12和α-MEM等，同时配合加入FBS、KOSR、L-谷氨酰胺、P/S、非必需氨基酸和FGF等。 Kang[8]等人报道，将iPSC培养基直接替换为含有10% FBS的DMEM培养基作用两周，传代后在预包被培养皿中对细胞持续传代，可获得成纤维细胞形态的iMSC细胞[9]。类似的诱导条件，使用α-MEM培养基[20]也能够获得。利用本法的整体诱导效率较低，如获得合格表型的iMSC（高表达 CD73、CD44、CD105、CD90；低表达CD19、CD34、CD45、HLA-DR等），且具备三系分化能力[10]，时间都要长达30-50天。（2）信号通路调节剂诱导iMSC形成通路抑制剂法是iPSCs诱导MSCs的一类常用方法，可快速高效的将iPSC诱导至MSC细胞表型并具有间充质干细胞功能。用于iPSC-MSCs诱导的抑制剂包括SB203580（p38-MAPK抑制剂）、SB431542（TGF-β抑制剂）、CHIR（GSK3抑制剂）、β-巯基乙醇、b-FGF等。 -SB203580 SB203580是一种吡啶咪唑类p38 MAPK抑制剂，对GAK、CK1、RIP2、c-Raf 和 GSK3等激酶也有抑制活性。p38-MAPK途径可促进MSC分化为表皮样细胞[11]，还可以抑制IL-2介导的T细胞增殖作用，在体内参与多种炎症反应或诱导细胞自噬。有文章报道SB203580能够促进iPSC细胞向中胚层表型的转化[12]，通过将iPSC悬浮形成拟胚体（EB），并在培养体系中加入一定浓度SB203580诱导拟胚体，将诱导后的拟胚体贴壁培养传代，28天后获得表面标志物合格的iMSC细胞，且传代20代后核型完整且细胞未衰老。 -SB431542 SB431542是TGF-β信号通路抑制剂，TGF信号通路是维持干细胞多能性的主要信号通路，抑制TGF通路可以诱导ESC和iPSC分化为MSC或神经元细胞[13]。Glaeser等人使用20 μM的SB431542经10-14天将ESC分步诱导为神经嵴细胞，再转换为有血清培养体系将神经嵴细胞向MSC样细胞转化[14]。Lee和Sun[15]等人在整个iMSC诱导过程中均加入10 μM SB431542，传代若干次后均获得具有三系分化能力的iMSC细胞系。不同研究者使用的SB431542作用浓度从1 μM向20 μM不等[16]，对iMSC的诱导效率未见明显差异。 -CHIR-99021 CHIR-99021是一种高度特异的糖原合成酶激酶-3（GSK-3）抑制剂，被证明可以促进BALB/c小鼠ES细胞的自我更新并维持其多能性。CHIR-99021涉及包括Wnt/β-catenin、TGF-β、Nodal和MAPK等多种信号通路[17]。不同浓度的CHIR99021常与 SB431542联合应用于iMSC的诱导分化。Harada等人[18]使用10 μM SB431542＋1 μM CHIR99021的化合物组合，按iPSC-神经嵴细胞-MSC样细胞的路线在21天左右成功诱导出间充质表型细胞。Winston等人[19]则使用4 μM SB431542＋4 μM CHIR99021＋10 ng/mL β-FGF在25天左右获得了iMSC。信号通路调节剂的加入与MSC培养基直接转换相比，诱导iMSC成熟的效率更高，整体分化时间被有效缩短，且获得的细胞无论从表型、三系分化能力及基因组表达方面，均与原代MSC细胞无明显差异[20]。 -β-巯基乙醇 β-巯基乙醇也是iMSC诱导过程中的常用添加物。Liang、McGrath、Hua和Lim等人，分别在iPSC培养体系中加入了浓度不同的β-巯基乙醇（终浓度分别为55 uM，0.1 mM，110mM[21]），30天左右获得成纤维样的iMSC细胞，经鉴定细胞表面标志物与三系分化能力与BM-MSC相似。（3）拟胚体法通过拟胚体（EB）介导的iMSC分化路径，能够在有限的培养体积中收获更多的目的细胞，有利于工业化和成本控制。然而培养过程整体需要的时间较长，且产生的细胞存在一定的异质性。研究者们通常在拟胚体形成及iMSC爬出阶段，在培养体系中加入化合物通路调节剂，以提高细胞向iMSC的富集效率。 Chen YS使用含有20% KOSR及0.1 μg/mL bFGF的DMEM-F12培养基，将iPSC悬浮培养形成EB，之后体系中加入10 μM浓度的SB431542以促进细胞爬出，接着经细胞传代获得iMSC [22]。Zhou等[23]开发了一种在生物反应器中大规模扩增胚胎干细胞的方法，将ESC悬浮培养后获得大量EB，接着使用含有KOSR的体系诱导EB分化，进一步诱导EB爬出，获得ES-MSC。研究者还进一步优化诱导体系，开发了诱导分化的新配方，在体系中添加一定浓度的b-FGF与TGFβ-1促进ES-MSC的爬出与成熟[24]。另外，包括Activin A，VEGF，BMP4，RA[25]等细胞因子也应用于经拟胚体分化的诱导过程中，分化天数在20-30天时间不等。由于篇幅所限，在下一篇讨论中，我们将对iMSC产品在不同疾病模型中的应用、临床级iPSC衍生细胞制品的最新研究进展以及新一代的iPSC衍生产品的开发策略这些方面进行进一步的探讨，笔者期待各位读者的反馈与进一步交流。 [1] A. Leyendecker, Jr., C.C.G. Pinheiro, M.T. Amano, D.F. Bueno, The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review, Front Immunol 9 (2018) 2056. [2] M. Arabpour, A. Saghazadeh, N. Rezaei, Anti-inflammatory and M2 macrophage polarization-promoting effect of mesenchymal stem cell-derived exosomes, Int Immunopharmacol 97 (2021) 107823. [3] G. Guo, Z. Tan, Y. Liu, F. Shi, J. She, The therapeutic potential of stem cell-derived exosomes in the ulcerative colitis and colorectal cancer, Stem Cell Res Ther 13(1) (2022) 138. [4] M. Miura, Y. Miura, H.M. Padilla-Nash, A.A. Molinolo, B. Fu, V. Patel, B.M. Seo, W. Sonoyama, J.J. Zheng, C.C. Baker, W. Chen, T. Ried, S. Shi, Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation, Stem Cells 24(4) (2006) 1095-103. [5] W.J. Rombouts, R.E. Ploemacher, Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture, Leukemia 17(1) (2003) 160-70. [6] A. Abdal Dayem, S.B. Lee, K. Kim, K.M. Lim, T.I. Jeon, J. Seok, A.S. Cho, Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming, Int J Mol Sci 20(8) (2019). [7] V. Dupuis, E. Oltra, Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells, World J Stem Cells 13(8) (2021) 1094-1111. [8] R. Kang, Y. Zhou, S. Tan, G. Zhou, L. Aagaard, L. Xie, C. Bunger, L. Bolund, Y. Luo, Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity, Stem Cell Res Ther 6(1) (2015) 144. [9] J. Zhang, J. Guan, X. Niu, G. Hu, S. Guo, Q. Li, Z. Xie, C. Zhang, Y. Wang, Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis, Journal of Translational Medicine 13(1) (2015). [10] M. Arakura, S.Y. Lee, T. Fukui, K. Oe, S. Takahara, T. Matsumoto, S. Hayashi, T. Matsushita, R. Kuroda, T. Niikura, Endochondral Bone Tissue Engineering Using Human Induced Pluripotent Stem Cells, Tissue Engineering Part A 28(3-4) (2022) 184-195. [11] S. Hu, L. Zhu, Y. Song, X. Zhao, Q. Chen, Y. Pan, J. Zhang, Y. Bai, H. Zhang, C. Shao, Radiation-induced abscopal reproductive effect is driven by TNF-α/p38 MAPK/Rac1 axis in Sertoli cells, Theranostics 11(12) (2021) 5742-5758. [12] J. Zhang, M. Chen, J. Liao, C. Chang, Y. Liu, A.A. Padhiar, Y. Zhou, G. Zhou, Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Hold Lower Heterogeneity and Great Promise in Biological Research and Clinical Applications, Frontiers in Cell and Developmental Biology 9 (2021). [13] Tanaka, Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity, Oncology Reports 24(6) (2010). [14] J.D. Glaeser, X. Bao, G. Kaneda, P. Avalos, P. Behrens, K. Salehi, X. Da, A. Chen, C. Castaneda, P. Nakielski, W. Jiang, W. Tawackoli, D. Sheyn, iPSC-neural crest derived cells embedded in 3D printable bio-ink promote cranial bone defect repair, Scientific Reports 12(1) (2022). [15] Y.S. Chen, R.A. Pelekanos, R.L. Ellis, R. Horne, E.J. Wolvetang, N.M. Fisk, Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells, Stem Cells Translational Medicine 1(2) (2012) 83-95. [16] D. Pal, H. Blair, J. Parker, S. Hockney, M. Beckett, M. Singh, R. Tirtakusuma, R. Nelson, H. McNeill, S.H. Angel, A. Wilson, S. Nizami, S. Nakjang, P. Zhou, C. Schwab, P. Sinclair, L.J. Russell, J. Coxhead, C. Halsey, J.M. Allan, C.J. Harrison, A.V. Moorman, O. Heidenreich, J. Vormoor, hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia, Cell Reports Medicine 3(8) (2022). [17] G.-B. Fu, W.-J. Huang, M. Zeng, X. Zhou, H.-P. Wu, C.-C. Liu, H. Wu, J. Weng, H.-D. Zhang, Y.-C. Cai, C. Ashton, M. Ding, D. Tang, B.-H. Zhang, Y. Gao, W.-F. Yu, B. Zhai, Z.-Y. He, H.-Y. Wang, H.-X. Yan, Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens, Cell Research 29(1) (2018) 8-22. [18] M. Sampaolesi, M. Fukuta, Y. Nakai, K. Kirino, M. Nakagawa, K. Sekiguchi, S. Nagata, Y. Matsumoto, T. Yamamoto, K. Umeda, T. Heike, N. Okumura, N. Koizumi, T. Sato, T. Nakahata, M. Saito, T. Otsuka, S. Kinoshita, M. Ueno, M. Ikeya, J. Toguchida, Derivation of Mesenchymal Stromal Cells from Pluripotent Stem Cells through a Neural Crest Lineage using Small Molecule Compounds with Defined Media, PLoS ONE 9(12) (2014). [19] T.S. Winston, K. Suddhapas, C. Wang, R. Ramos, P. Soman, Z. Ma, Serum-Free Manufacturing of Mesenchymal Stem Cell Tissue Rings Using Human-Induced Pluripotent Stem Cells, Stem Cells International 2019 (2019) 1-11. [20] M. Yoshimatsu, H. Ohnishi, C. Zhao, Y. Hayashi, F. Kuwata, S. Kaba, H. Okuyama, Y. Kawai, N. Hiwatashi, Y. Kishimoto, T. Sakamoto, M. Ikeya, K. Omori, In vivo regeneration of rat laryngeal cartilage with mesenchymal stem cells derived from human induced pluripotent stem cells via neural crest cells, Stem Cell Research 52 (2021). [21] S.W. Lim, K.W. Kim, B.M. Kim, Y.J. Shin, K. Luo, Y. Quan, S. Cui, E.J. Ko, B.H. Chung, C.W. Yang, Alleviation of renal ischemia/reperfusion injury by exosomes from induced pluripotent stem cell-derived mesenchymal stem cells, The Korean Journal of Internal Medicine 37(2) (2022) 411-424. [22] Y.S. Chen, R.A. Pelekanos, R.L. Ellis, R. Horne, E.J. Wolvetang, N.M. Fisk, Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells, Stem cells translational medicine 1(2) (2012) 83-95. [23] X. Li, R. Ma, Q. Gu, L. Liang, L. Wang, Y. Zhang, X. Wang, X. Liu, Z. Li, J. Fang, J. Wu, Y. Wang, W. Li, B. Hu, L. Wang, Q. Zhou, J. Hao, A fully defined static suspension culture system for large-scale human embryonic stem cell production, Cell death & disease 9(9) (2018) 892. [24] J. Wu, D. Song, Z. Li, B. Guo, Y. Xiao, W. Liu, L. Liang, C. Feng, T. Gao, Y. Chen, Y. Li, Z. Wang, J. Wen, S. Yang, P. Liu, L. Wang, Y. Wang, L. Peng, G.N. Stacey, Z. Hu, G. Feng, W. Li, Y. Huo, R. Jin, N. Shyh-Chang, Q. Zhou, L. Wang, B. Hu, H. Dai, J. Hao, Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lun [25] M. Karam, I. Younis, N.R. Elareer, S. Nasser, E.M. Abdelalim, Scalable Generation of Mesenchymal Stem Cells and Adipocytes from Human Pluripotent Stem Cells, Cells 9(3) (2020). 药事纵横征稿启事

细胞疗法免疫疗法

100 项与曲弗明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03362	曲弗明	D03	DB06244

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
牙周炎	日本	Kaken Pharmaceutical Co., Ltd.	2016-09-28
褥疮	日本	Kaken Pharmaceutical Co., Ltd.	2001-04-04
皮肤溃疡	日本	Kaken Pharmaceutical Co., Ltd.	2001-04-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病足溃疡	临床前	匈牙利	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床前	捷克	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床前	法国	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床前	意大利	Olympus Biotech Corp.	2010-11-01
牙槽骨质丢失	临床前	日本	Kaken Pharmaceutical Co., Ltd.	2008-08-01
牙周附着丢失	临床前	日本	Kaken Pharmaceutical Co., Ltd.	2008-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01217463 (TRANS-South, CTgov)	临床3期	糖尿病足溃疡	201	Trafermin 0.01% spray (Trafermin 0.01% Spray)	廠範醖築鹽淵鑰鬱觸糧(夢淵蓋選簾醖鏇選觸艱) = 淵艱蓋壓窪襯鏇製鬱遞餘壓蓋鹽遞網蓋網鬱獵 (範繭鹹齋範願壓齋艱觸, 艱積網獵範蓋鬱艱繭壓 ~ 簾蓋夢願願鹹餘遞淵鹹)	-	2014-08-05
				Trafermin 0.01% spray (Matching Placebo Spray)	廠範醖築鹽淵鑰鬱觸糧(夢淵蓋選簾醖鏇選觸艱) = 廠獵願膚構選製糧淵糧餘壓蓋鹽遞網蓋網鬱獵 (範繭鹹齋範願壓齋艱觸, 窪襯網夢淵衊構觸廠壓 ~ 鹽廠夢選簾鹽簾構繭憲)
NCT01217476 (TRANS-North, CTgov)	临床3期	糖尿病足溃疡	207	Trafermin (Trafermin)	窪簾淵觸鑰獵窪製簾夢(艱製築積憲窪構蓋鬱選) = 廠餘膚餘衊蓋夢鹹簾網築淵壓襯鹹積構範範築 (網齋蓋網繭艱蓋顧壓簾, 築餘選鏇餘遞餘鹽選膚 ~ 襯築膚鏇襯壓選遞鏇艱) 更多	-	2014-08-05
				placebo (Placebo)	窪簾淵觸鑰獵窪製簾夢(艱製築積憲窪構蓋鬱選) = 蓋鹹遞顧築鏇鑰鹹簾醖築淵壓襯鹹積構範範築 (網齋蓋網繭艱蓋顧壓簾, 餘艱膚襯齋糧遞憲艱願 ~ 艱繭艱製積觸鏇簾膚鏇) 更多
ARVO2003	N/A	腱鞘囊肿	-	Adenosine 10 µM	積衊範夢壓壓鬱壓顧襯(築糧鹽繭願鬱選窪觸衊) = 鏇製窪網網蓋選鹽鑰鹹餘繭選蓋壓襯襯衊繭獵 (選繭襯願選蓋膚鹹憲膚 )	-	2003-05-01
				Adenosine 100 µM	積衊範夢壓壓鬱壓顧襯(築糧鹽繭願鬱選窪觸衊) = 窪選鹽構齋鹹膚鹹範願餘繭選蓋壓襯襯衊繭獵 (選繭襯願選蓋膚鹹憲膚 )
ARVO2002	N/A	病理性新生血管	18	Medpor(R) soaked with bFGF	範淵憲獵蓋壓衊壓醖糧(醖鬱範選築夢簾醖襯製) = 艱夢顧網選顧鹹願廠壓選艱醖齋夢築淵夢鬱醖 (淵鑰遞觸製窪繭鏇製淵 )	积极	2002-12-01
				Basic Fibroblast Growth Factor (Unsoaked Medpor(R))	範淵憲獵蓋壓衊壓醖糧(醖鬱範選築夢簾醖襯製) = 遞範範糧構願襯簾壓窪選艱醖齋夢築淵夢鬱醖 (淵鑰遞觸製窪繭鏇製淵 )